Must See: Grab This Emerging Opportunity Before it Slips Away
Here is the latest financial fact sheet of IND. SWIFT. For more details, see the IND. SWIFT quarterly results and IND. SWIFT share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -2.0 |
No. of shares | m | 54.16 |
1 Week | % | 16.4 |
1 Month | % | 30.6 |
1 Year | % | 186.8 |
52 week H/L | Rs | 31.1/7.8 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
IND. SWIFT EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 11 | 6 | 5 | 19 | 15 | |
Low | Rs | 5 | 2 | 2 | 4 | 7 | |
Sales per share (Unadj.) | Rs | 53.4 | 60.8 | 65.7 | 73.4 | 75.9 | |
Earnings per share (Unadj.) | Rs | 1.5 | -3.5 | -5.5 | -3.7 | 4.8 | |
Diluted earnings per share | Rs | 1.5 | -3.5 | -5.5 | -3.7 | 4.8 | |
Cash flow per share (Unadj.) | Rs | 7.8 | 2.7 | 0.5 | 2.2 | 10.1 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | -125.0 | -131.7 | -128.4 | -133.0 | -130.1 | |
Adj. book value per share | Rs | -124.9 | -131.7 | -128.3 | -133.0 | -130.1 | |
Shares outstanding (eoy) | m | 54.16 | 54.16 | 54.16 | 54.16 | 54.16 | |
Price / Sales ratio | x | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | |
Avg P/E ratio | x | 5.3 | -1.1 | -0.6 | -3.0 | 2.2 | |
P/CF ratio (eoy) | x | 1.0 | 1.5 | 6.4 | 5.1 | 1.0 | |
Price / Book Value ratio | x | -0.1 | 0 | 0 | -0.1 | -0.1 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 433 | 216 | 184 | 610 | 572 | |
Total wages/salary | Rs m | 463 | 489 | 512 | 578 | 637 |
IND. SWIFT INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 2,890 | 3,295 | 3,561 | 3,977 | 4,110 | |
Other income | Rs m | 84 | 224 | 152 | 235 | 119 | |
Total revenues | Rs m | 2,975 | 3,519 | 3,713 | 4,213 | 4,228 | |
Gross profit | Rs m | 375 | 297 | 402 | 461 | 1,026 | |
Depreciation | Rs m | 340 | 336 | 327 | 321 | 287 | |
Interest | Rs m | 38 | 352 | 522 | 572 | 598 | |
Profit before tax | Rs m | 82 | -167 | -295 | -196 | 260 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 0 | 25 | 3 | 4 | 0 | |
Profit after tax | Rs m | 82 | -191 | -298 | -200 | 260 | |
Gross profit margin | % | 13.0 | 9.0 | 11.3 | 11.6 | 25.0 | |
Effective tax rate | % | 0 | -14.8 | -1.1 | -2.1 | 0 | |
Net profit margin | % | 2.8 | -5.8 | -8.4 | -5.0 | 6.3 |
IND. SWIFT BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 1,935 | 2,286 | 2,652 | 2,424 | 2,734 | |
Current liabilities | Rs m | 6,159 | 6,541 | 7,062 | 7,180 | 9,363 | |
Net working cap to sales | % | -146.1 | -129.1 | -123.9 | -119.6 | -161.3 | |
Current ratio | x | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | |
Inventory Days | Days | 144 | 114 | 153 | 133 | 115 | |
Debtors Days | Days | 954 | 1,043 | 1,107 | 832 | 929 | |
Net fixed assets | Rs m | 4,049 | 3,730 | 4,064 | 3,893 | 3,758 | |
Share capital | Rs m | 108 | 108 | 108 | 108 | 108 | |
"Free" reserves | Rs m | -6,876 | -7,240 | -7,060 | -7,312 | -7,155 | |
Net worth | Rs m | -6,767 | -7,131 | -6,952 | -7,203 | -7,047 | |
Long term debt | Rs m | 6,447 | 6,442 | 6,442 | 6,193 | 4,031 | |
Total assets | Rs m | 5,984 | 6,016 | 6,716 | 6,318 | 6,492 | |
Interest coverage | x | 3.2 | 0.5 | 0.4 | 0.7 | 1.4 | |
Debt to equity ratio | x | -1.0 | -0.9 | -0.9 | -0.9 | -0.6 | |
Sales to assets ratio | x | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | |
Return on assets | % | 2.0 | 2.7 | 3.3 | 5.9 | 13.2 | |
Return on equity | % | -1.2 | 2.7 | 4.3 | 2.8 | -3.7 | |
Return on capital | % | -37.3 | -26.9 | -44.5 | -37.2 | -28.4 | |
Exports to sales | % | 69.5 | 69.5 | 74.2 | 73.7 | 68.8 | |
Imports to sales | % | 3.2 | 4.1 | 5.0 | 6.0 | 5.3 | |
Exports (fob) | Rs m | 2,010 | 2,290 | 2,643 | 2,932 | 2,827 | |
Imports (cif) | Rs m | 93 | 134 | 176 | 239 | 217 | |
Fx inflow | Rs m | 2,034 | 2,344 | 2,682 | 2,996 | 2,947 | |
Fx outflow | Rs m | 137 | 187 | 260 | 283 | 313 | |
Net fx | Rs m | 1,897 | 2,157 | 2,422 | 2,713 | 2,634 |
IND. SWIFT CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 428 | 346 | 832 | 502 | 730 | |
From Investments | Rs m | -137 | -114 | -167 | -184 | -293 | |
From Financial Activity | Rs m | -130 | -262 | -542 | -446 | -466 | |
Net Cashflow | Rs m | 160 | -30 | 122 | -128 | -29 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: S R Mehta | COMP SEC: Amrender Kumar Yadav | YEAR OF INC: 1986 | BSE CODE: 524652 | FV (Rs): 2 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare IND. SWIFT With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Indian share markets continued the momentum as the session progressed and ended higher.